NCT01488344Unknown1 期
A Single-arm, Open Label, Multi-center Phase I/II Trial to Assess the Safety and Efficacy of BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With AML Unfit for an Intensive Induction Therapy
University Hospital Muenster1 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2012年3月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 140
- 试验地点
- 1
- 主要终点
- Phase II: overall response rate (ORR)
研究概览
简要总结
RATIONALE: Low-dose cytarabine works in a minority of elderly patients with an acute myeloid leukemia unfit for intensive induction therapy by killing of leukemia cells. Addition of BIBF1120 to low-dose cytarabine might enhance the killing of leukemia cells.
PURPOSE: This phase I / II trial is studying how safe BIBF1120 can be combined with low-dose cytarabine (phase I) and how well the combination of low-dose cytarabine and BIBF1120 works in elderly patients with acute myeloid leukemia unfit for intensive chemotherapy (phase II).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with newly diagnosed AML (except APL) according to the FAB or WHO classification, including AML evolving from MDS or other hematological diseases and AML after previous cytotoxic therapy or radiation (secondary AML), with medical contraindications against or not willing to receive a standard induction and consolidation therapy.
- •Bone marrow aspirate or biopsy must contain > 20% blasts of all nucleated cells. In AML FAB M6 ≥ 30% of non-erythroid cells in the bone marrow must be leukemic blasts. In patients with 20-30% blasts, the indication for a treatment with hypomethylating agents (5-azacitidine or decitabine) should be considered prior to inclusion into the trial.
- •Age ≥ 60 years
- •Informed consent, personally signed and dated to participate in the study
- •Male patients enrolled in this trial must use adequate barrier birth control measures during the course of treatment and for at least 3 months after the last administration of study therapy (low-dose cytarabine and/or BIBF 1120).
排除标准
- •Patients with 20-30% bone marrow blasts which are qualifying for and consenting into a therapy with hypomethylating agents
- •Patients who are eligible for and consenting into a standard chemotherapy
- •Known central nervous system manifestation of AML
- •Inadequate liver function (ALT and AST ≥ 2.5 x ULN) if not caused by leukemic infiltration
- •Known chronically active hepatitis C infection or acute hepatitis
- •Chronically impaired renal function (creatinin clearance < 30 ml/min)
- •Uncontrolled hypertension with a resting pressure systolic > 160 mmHg or diastolic > 95 mmHg despite adequate treatment
- •severe trauma or surgery within 4 weeks of study entry
- •severe, non-healing wounds, ulcer or fracture
- •Uncontrolled active infection
- •Concurrent malignancies other than AML or other severe diseases which in the opinion of the investigator are likely to influence the endpoint assessment
- •Hypersensitivity to cytarabine (not including drug fever or exanthema)
- •Previous treatment of AML except hydroxyurea up to 24 hours before study medication
- •Previous therapy with tyrosine kinase inhibitors or angiogenesis inhibitors
- •Parallel participation in another clinical trial for the same indication. Eligibility of patients with investigational drug therapy outside of this trial during or within 4 weeks of study entry should be discussed with the study office prior to study entry
- •Any severe concomitant condition, which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol
研究组 & 干预措施
BIBF 1120
Experimental
干预措施: triple kinase inhibitor BIBF1120 (Drug)
结局指标
主要结局
Phase II: overall response rate (ORR)
时间窗: up to 6 month
Phase I: defining maximum tolerated dose (MTD)
时间窗: 4 weeks
次要结局
- number of participants with adverse events as a measure of safety and tolerability(up to 12 month)
- relapse-free survival (RFS)of the responding patients(up to 12 month)
- Complete remission (CR) rate(up to 12 month)
- overall survival (OS)(up to 12 month)
- ORR rate of the Flt3-mutated patients versus the Flt3-wildtype patients(up to 12 month)
- CR rate of the Flt3-mutated patients versus the Flt3-wildtype patients(up to 12 month)
- OS of the Flt3-mutated patients versus the Flt3-wildtype patients(up to 12 month)
- time to response (CR, CRp, CRi) of the responding patients(up to 12 month)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years OldAcute Myeloid LeukemiaNCT02432911Jianxiang Wang300
已完成
不适用
Treatment With Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) With Acute Myeloid Leukemia: A Single Institution Experience.Acute Myeloid LeukemiaNCT03350152Hospices Civils de Lyon302
已完成
3 期
Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 MutationAcute Myeloid Leukemia (AML)NCT01237808University of Ulm144
进行中（未招募）
不适用
Decitabine-cytarabine chemotherapy in elderly AML and high risk MDS patients (> 65 years) with high early mortality riskAcute myeloid leukemia and high risk myelodysplasiaEUCTR2015-004896-60-NLeiden University Medical Center
已完成
2 期
Decitabine-cytarabine chemotherapy in elderly AML and high risk MDS patients (> 65 years) with high early mortality riskmyelodysplasia10024324acute leukemiaNL-OMON42455eids Universitair Medisch Centrum19